Veröffentlichungen
Highlits vom Kongress ASCO 2022 zur Therapie mit CDK4/6-Inhibitoren
Statement Dr. med. Thomas Göhler zur PALOMA-2-Studie: Postmenopausale Frauen mit HR+ / HER2- metastaiertem Brustkrebs ohne Vorbehandlung
CLL – Patient registry (Bendamustine original vs. generics)
Oktober 2018
- Autoren: H.Linde, K.Blumenstengel, T.Göhler, C.Spohn, R.Göttel, M.O.Zahn, Project team of Internal Oncology (PIO)
- Institution: Specialized oncology practice Potsdam, Specialized oncology practice Eisenach, Specialized oncology practice Dresden, Specialized oncology practice Halle, rgb Onkologisches Management GmbH Sarstedt, Specialized oncology practice Goslar
- DGHO 2018 (Abstract)
Evaluation of safety, tolerability and activity of Sunitinib in patients (pts) with advanced or metastatic renal cell carcinoma (a/mRCC) in routine clinical practice
Oktober 2018
- Autoren: Bergmann L, Woike M., Krekeler G., Steiner T., Goebell P.J., Göhler T., Harich H.-D., Herrmann E., Rebmann U., Krüger H.
- Institution: Universitätsklinikum Frankfurt, Medizinische Klinik II; Pfizer Pharma GmbH, Berlin; Helios Klinikum Erfurt, Urologie; AURONTE, Universitätsklinikum Erlangen; Onkozentrum Dresden; Onkologie Hof MVZ GmbH, Universitätsklinikum Münster, Urologie; Urologische Klinik Diakonissenkrankenhaus Dessau;
- DGHO 2018 (Poster)
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer – Results of the safety run-in phase II AVETUX trial (AIO-KRK-0216)
Juni 2018
- Autoren: Stein A., Binder M., Al-Batran S.E., Hinke A., Waberer L., Goekkurt E., Statovci D., Depenbusch R., Riera-Knorrenschild J., Lorenzen S., Ettrich T., Doerfel S., Bokemeyer C., Hegewisch-Becker S.
- Institution: University Medical Center Hamburg-Eppendorf, Hamburg; Institute of Clinical Cancer Research, Krankenhaus Nordwest, Frankfurt; CCRC, Düsseldorf; 4Hematology-Oncology Practice Hamburg (HOPE), Hamburg; Private Practice Onkodoc GmbH Gütersloh; University Clinics Giessen-Marburg; Rechts der Isar Hospital, Technical University of Munich Germany; Center for Internal Medicine I, University of Ulm; Private Practice Onkozentrum Dresden
- ASCO 2018 (Poster + Abstract)
Aflibercept in the 2nd-/3rd- line therapy of the colorectal carcinoma
Februar 2018
- Autoren: T.Krambach, P. Bartels, O. Rubanov, M.Teich, W. Elsel, T.Göhler, Project Group of Internal Oncology (PIO)
- Institution: Specialized oncology practice Goslar, rgb Onkologisches Management GmbH Sarstedt, Speciallized oncology practice Hameln, Specialized oncology practice Chemnitz, Specialized oncology practice Glauchau, Specialized oncology practice Dresden
- DKK 2018 (Abstract)
Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study
Februar 2018
- Autoren: P. Dall, T.Koch, T. Göhler, J. Selbach, A. Ammon, J. Eggert, N. Gazawi, D. Rezek, A. Wischnik, C. Hielscher, N. Schleif, U. Cirrincione, A. Hinke, G. Feisel-Schwickardi
- Institution: Department of Obstetrics and Gynaecology and Breast Cancer Center, Klinikum Lüneburg; Breast Center, Klinikum Nürnberg; Onkozentrum Dresden/Freiberg; Oncology Practice, Duisburg; Oncology Practice, Göttingen; Oncology Practice, Moers; Gyneco-Oncology Practice, Leipzig; Gynecology Department, Marien-Hospital, Wesel; Department of Gynecology, Klinikum Ausgsburg; Gyneco-Oncology Practice, Stralsund; Roche Pharma AG, grenzach-Wyhlen; WiSP Research Institute, Langenfeld; Department of Obstetrics and Gynecology and Breast Cancer Center, Klinikum Kassel
- Journal BMC Cancer 2018 (18: 51) / Published online 2018 Jan 8. doi: 10.1186/s12885-017-3857-5